Caffeine provokes adverse interactions with 3,4- methylenedioxymethamphetamine (MDMA, 'ecstasy') and related psychostimulants: Mechanisms and mediators

British Journal of Pharmacology

Volumn 167, Issue 5, 2012, Pages 946-959

  Vanattou Saifoudine N ^a   McNamara, R ^a   Harkin, A ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

3,4 methylenedioxymethamphetamine; adenosine; caffeine; cardiotoxicity; dopamine; hyperthermia; phosphodiesterase; Psychostimulants; rat; recreational drug use; serotonin

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; ADENOSINE RECEPTOR; ADENOSINE TRIPHOSPHATE; ALCOHOL; AMFEBUTAMONE; CAFFEINE; CYTOCHROME P450; DEXAMPHETAMINE; DOPAMINE; DOPAMINE RECEPTOR; EPHEDRINE; PSYCHOSTIMULANT AGENT; RECREATIONAL DRUG; SEROTONIN; UNCOUPLING PROTEIN 1; UNCOUPLING PROTEIN 2; UNCOUPLING PROTEIN 3;

ACUTE TOXICITY; ADVERSE OUTCOME; ALCOHOLISM; CARDIOTOXICITY; CHEMICAL INTERACTION; CONVULSION; CORE TEMPERATURE; DISEASE PREDISPOSITION; DISEASE SEVERITY; DOPAMINE RELEASE; DOSE RESPONSE; DRUG ABUSE; DRUG FATALITY; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; FOOD DRUG INTERACTION; FOOD INTAKE; HEART ARRHYTHMIA; HIGH TEMPERATURE; HUMAN; HYPERTENSION; LONG TERM EXPOSURE; MORTALITY; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BLOCKING; REINFORCEMENT; REVIEW; RISK ASSESSMENT; SEIZURE; SEIZURE THRESHOLD; SEROTONIN RELEASE; SEROTONINERGIC SYSTEM; TACHYCARDIA; THERMOGENESIS;

ANIMALS; CAFFEINE; CENTRAL NERVOUS SYSTEM STIMULANTS; DRUG INTERACTIONS; HALLUCINOGENS; HUMANS; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; STREET DRUGS;

EID: 84867321061     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2012.02065.x     Document Type: Review

References (97)

1. Abbott PJ, (1986). Caffeine: a toxicological overview. Med J Aust 145: 518-521. (Pubitemid 17027549)
2. 1 receptor ligand, induced by cyclic AMP-dependent protein kinase in rat brain. Brain Res 952: 211-217.
3. Arria AM, O'Brien MC, (2011). The 'high' risk of energy drinks. JAMA 305: 600-601.
4. Badon LA, Hicks A, Lord K, Ogden BA, Meleg-Smith S, Varner KJ, (2002). Changes in cardiovascular responsiveness and cardiotoxicity elicited during binge administration of ecstasy. J Pharmacol Exp Ther 302: 898-907. (Pubitemid 34920209)
5. Bedingfield JB, King DA, Holloway FA, (1998). Cocaine and caffeine: conditioned place preference, locomotor activity, and additivity. Pharmacol Biochem Behav 61: 291-296. (Pubitemid 28498211)
6. Benac N, (2011). United States Food and Drug Administration signals crackdown on caffeinated alcohol drinks. CMAJ 183: E47-E48.
7. Benowitz NL, Jacob P, Mayan H, Denaro C, (1995). Sympathomimetic effects of paraxanthine and caffeine in humans. Clin Pharmacol Ther 58: 684-691. (Pubitemid 26018853)
8. Boison D, (2011). Methylxanthines, seizures, and excitotoxicity. Handb Exp Pharmacol 200: 251-266.
9. 1 receptor-mediated modulation of dopamine release in different striatal compartments. J Neurochem 101: 355-363. (Pubitemid 46525280)
10. Brockwell NT, Eikelboom R, Beninger RJ, (1991). Caffeine-induced place and taste conditioning: production of dose-dependent preference and aversion. Pharmacol Biochem Behav 38: 513-517.
11. Burgess C, O'Donohue A, Gill M, (2000). Agony and ecstasy: a review of MDMA effects and toxicity. Eur Psychiatry 15: 287-294. (Pubitemid 30643932)
12. Camarasa J, Pubill D, Escubedo E, (2006). Association of caffeine to MDMA does not increase antinociception but potentiates adverse effects of this recreational drug. Brain Res 1111: 72-82. (Pubitemid 44331182)
13. Cauli O, Morelli M, (2005). Caffeine and the dopaminergic system. Behav Pharmacol 16: 63-77. (Pubitemid 40477532)
14. Cauli O, Pinna A, Valentini V, Morelli M, (2003). Subchronic caffeine exposure induces sensitization to caffeine and cross-sensitization to amphetamine ipsilateral turning behavior independent from dopamine release. Neuropsychopharmacology 28: 1752-1759. (Pubitemid 41070840)
15. Chen JF, Yu L, Shen HY, He JC, Wang X, Zheng R, (2010). What knock-out animals tell us about the effects of caffeine. J Alzheimers Dis 20 (Suppl. 1): S17-S24.
16. Childs E, Hohoff C, Deckert J, Xu K, Badner J, de Wit H, (2008). Association between ADORA2A and DRD2 polymorphisms and caffeine-induced anxiety. Neuropsychopharmacology 33: 2791-2800.
17. Cole C, Jones L, McVeigh J, Kicman A, Syed Q, Bellis M, (2011). Adulterants in illicit drugs: a review of empirical evidence. Drug Test Anal 3: 89-96.
18. Comer SD, Carroll ME, (1996). Oral caffeine pretreatment produced modest increases in smoked cocaine self-administration in rhesus monkeys. Psychopharmacology (Berl) 126: 281-285. (Pubitemid 26276698)
19. Derlet RW, Tseng JC, Albertson TE, (1992). Potentiation of cocaine and d-amphetamine toxicity with caffeine. Am J Emerg Med 10: 211-216.
20. Devlin RJ, Henry JA, (2008). Clinical review: major consequences of illicit drug consumption. Crit Care 12: 202.
21. Di Matteo V, Di Giovanni G, Pierucci M, Esposito E, (2008). Serotonin control of central dopaminergic function: focus on in vivo microdialysis studies. Prog Brain Res 172: 7-44.
22. Donovan JL, DeVane CL, (2001). A primer on caffeine pharmacology and its drug interactions in clinical psychopharmacology. Psychopharmacol Bull 35: 30-48.
23. Dulloo AG, (1993). Ephedrine, xanthines and prostaglandin-inhibitors: actions and interactions in the stimulation of thermogenesis. Int J Obes Relat Metab Disord 17 (Suppl. 1): S35-S40. (Pubitemid 23092813)
24. Dulloo AG, Seydoux J, Girardier L, (1991). Peripheral mechanisms of thermogenesis induced by ephedrine and caffeine in brown adipose tissue. Int J Obes 15: 317-326.
25. Dulloo AG, Seydoux J, Girardier L, (1992). Potentiation of the thermogenic antiobesity effects of ephedrine by dietary methylxanthines: adenosine antagonism or phosphodiesterase inhibition? Metabolism 41: 1233-1241.
26. Dulloo AG, Seydoux J, Girardier L, (1994). Paraxanthine (metabolite of caffeine) mimics caffeine's interaction with sympathetic control of thermogenesis. Am J Physiol 267: E801-E804.
27. Dumont GJ, Verkes RJ, (2006). A review of acute effects of 3,4-methylenedioxymethamphetamine in healthy volunteers. J Psychopharmacol 20: 176-187.
28. Endo M, (2009). Calcium-induced calcium release in skeletal muscle. Physiol Rev 89: 1153-1176.
29. Ferré S, (2010). Role of the central ascending neurotransmitter systems in the psychostimulant effects of caffeine. J Alzheimers Dis 20 (Suppl. 1): S35-S49.
30. 2A receptor heteromers: new targets for caffeine in the brain. Front Biosci 13: 2391-2399. (Pubitemid 351589262)
31. Fredholm BB, Bättig K, Holmén J, Nehlig A, Zvartau EE, (1999). Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev 51: 83-133. (Pubitemid 29113867)
32. Gasior M, Jaszyna M, Peters J, Goldberg SR, (2000). Changes in the ambulatory activity and discriminative stimulus effects of psychostimulant drugs in rats chronically exposed to caffeine: effect of caffeine dose. J Pharmacol Exp Ther 295: 1101-1111.
33. Giorgi FS, Lazzeri G, Natale G, Iudice A, Ruggieri S, Paparelli A, et al,. (2006). MDMA and seizures: a dangerous liaison? Ann N Y Acad Sci 1074: 357-364. (Pubitemid 44532840)
34. Girault JA, Greengard P, (2004). The neurobiology of dopamine signalling. Arch Neurol 61: 641-644.
35. Green AR, Mechan AO, Elliott JM, O'Shea E, Colado MI, (2003). The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy'). Pharmacol Rev 55: 463-508. (Pubitemid 37013213)
36. Green AR, O'Shea E, Colado MI, (2004). A review of the mechanisms involved in the acute MDMA (ecstasy)-induced hyperthermic response. Eur J Pharmacol 500: 3-13. (Pubitemid 39303992)
37. Green AR, O'Shea E, Saadat KS, Elliott JM, Colado MI, (2005). Studies on the effect of MDMA ('ecstasy') on the body temperature of rats housed at different ambient room temperatures. Br J Pharmacol 146: 306-312. (Pubitemid 43079971)
38. Green TA, Schenk S, (2002). Dopaminergic mechanism for caffeine-produced cocaine seeking in rats. Neuropsychopharmacology 26: 422-430. (Pubitemid 34260992)
39. Griffiths RR, Woodson PP, (1988). Reinforcing properties of caffeine: studies in humans and laboratory animals. Pharmacol Biochem Behav 29: 419-427. (Pubitemid 19258283)
40. Gudelsky GA, Yamamoto BK, (2008). Actions of 3,4- methylenedioxymethamphetamine (MDMA) on cerebral dopaminergic, serotonergic and cholinergic neurons. Pharmacol Biochem Behav 90: 198-207. (Pubitemid 351787346)
41. Holmgren P, Norden-Pettersson L, Ahlner J, (2004). Caffeine fatalities-four case reports. Forensic Sci Int 139: 71-73. (Pubitemid 37543713)
42. Iyo M, Maeda Y, Inada T, Kitao Y, Sasaki H, Fukui S, (1995). The effects of a selective cAMP phosphodiesterase inhibitor, rolipram, on methamphetamine-induced behavior. Neuropsychopharmacology 13: 33-39.
43. Iyo M, Bi Y, Hashimoto K, Inada T, Fukui S, (1996). Prevention of methamphetamine-induced behavioral sensitization in rats by a cyclic AMP phosphodiesterase inhibitor, rolipram. Eur J Pharmacol 312: 163-170. (Pubitemid 26325675)
44. Jaehne EJ, Salem A, Irvine RJ, (2005). Effects of 3,4- methylenedioxymethamphetamine and related amphetamines on autonomic and behavioral thermoregulation. Pharmacol Biochem Behav 81: 485-496. (Pubitemid 40966794)
45. Jain R, Holtzman SG, (2005). Caffeine induces differential cross tolerance to the amphetamine-like discriminative stimulus effects of dopaminergic agonists. Brain Res Bull 65: 415-421.
46. Jaszyna M, Gasior M, Shoaib M, Yasar S, Goldberg SR, (1998). Behavioral effects of nicotine, amphetamine and cocaine under a fixed-interval schedule of food reinforcement in rats chronically exposed to caffeine. Psychopharmacology (Berl) 140: 257-271. (Pubitemid 28562445)
47. Jiang D, Sibley DR, (1999). Regulation of D(1) dopamine receptors with mutations of protein kinase phosphorylation sites: attenuation of the rate of agonist-induced desensitization. Mol Pharmacol 56: 675-683. (Pubitemid 29491168)
48. Johnson MW, Strain EC, Griffiths RR, (2010). Effects of oral caffeine pretreatment on response to intravenous nicotine and cocaine. Exp Clin Psychopharmacol 18: 305-315.
49. Jose PA, Eisner GM, Felder RA, (2003). Regulation of blood pressure by dopamine receptors. Nephron Physiol 95: 19-27.
50. Klingler W, Heffron JJ, Jurkat-Rott K, O'Sullivan G, Alt A, Schlesinger F, et al,. (2005). 3,4-Methylenedioxymethamphetamine (ecstasy) activates skeletal muscle nicotinic acetylcholine receptors. J Pharmacol Exp Ther 314: 1267-1273. (Pubitemid 41205993)
51. Knapp CM, Foye MM, Cottam N, Ciraulo DA, Kornetsky C, (2001). Adenosine agonists CGS 21680 and NECA inhibit the initiation of cocaine self-administration. Pharmacol Biochem Behav 68: 797-803. (Pubitemid 32411619)
52. Kogure A, Sakane N, Takakura Y, Umekawa T, Yoshioka K, Nishino H, et al,. (2002). Effects of caffeine on the uncoupling protein family in obese yellow KK mice. Clin Exp Pharmacol Physiol 29: 391-394. (Pubitemid 34535358)
53. Kot M, Daniel WA, (2008). Caffeine as a marker substrate for testing cytochrome P450 activity in human and rat. Pharmacol Rep 60: 789-797.
54. Lindskog M, Svenningsson P, Pozzi L, Kim Y, Fienberg AA, Bibb JA, et al,. (2002). Involvement of DARPP-32 phosphorylation in the stimulant action of caffeine. Nature 418: 774-778.
55. McGrath J, Drummond G, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
56. McNamara R, Kerans A, O'Neill B, Harkin A, (2006). Caffeine promotes hyperthermia and serotonergic loss following co-administration of the substituted amphetamines, MDMA ('Ecstasy') and MDA ('Love'). Neuropharmacology 50: 69-80. (Pubitemid 43069773)
57. McNamara R, Maginn M, Harkin A, (2007). Caffeine induces a profound and persistent tachycardia in response to MDMA ('ecstasy') administration. Eur J Pharmacol 555: 194-198. (Pubitemid 46048811)
58. Magkos F, Kavouras SA, (2004). Caffeine and ephedrine: physiological, metabolic and performance-enhancing effects. Sports Med 34: 871-889. (Pubitemid 39490756)
59. Marczinski CA, Fillmore MT, (2006). Clubgoers and their trendy cocktails: implications of mixing caffeine into alcohol on information processing and subjective reports of intoxication. Exp Clin Psychopharmacol 14: 450-458. (Pubitemid 44789966)
60. Maurer HH, Bickeboeller-Friedrich J, Kraemer T, Peters FT, (2000). Toxicokinetics and analytical toxicology of amphetamine-derived designer drugs ('ecstasy'). Toxicol Lett 112-113: 133-142. (Pubitemid 30138114)
61. Mehta MC, Jain AC, Billie M, (2004). Effects of cocaine and caffeine alone and in combination on cardiovascular performance: an experimental hemodynamic and coronary flow reserve study in a canine model. Int J Cardiol 97: 225-232. (Pubitemid 39286840)
62. Mills EM, Rusyniak DE, Sprague JE, (2004). The role of the sympathetic nervous system and uncoupling proteins in the thermogenesis induced by 3,4-methylenedioxymethamphetamine. J Mol Med (Berl) 82: 787-799.
63. Morelli M, Simola N, (2011). Methylxanthines and drug dependence: a focus on interactions with substances of abuse. Handb Exp Pharmacol 200: 483-507.
64. Mori T, Baba J, Ichimaru Y, Suzuki T, (2000). Effects of rolipram, a selective inhibitor of phosphodiesterase 4, on hyperlocomotion induced by several abused drugs in mice. Jpn J Pharmacol 83: 113-118. (Pubitemid 30449739)
65. Mumford GK, Holtzman SG, (1991). Qualitative differences in the discriminative stimulus effects of low and high doses of caffeine in the rat. J Pharmacol Exp Ther 258: 857-865.
66. Mumford GK, Evans SM, Kaminski BJ, Preston KL, Sannerud CA, Silverman K, et al,. (1994). Discriminative stimulus and subjective effects of theobromine and caffeine in humans. Psychopharmacology (Berl) 115: 1-8. (Pubitemid 24207754)
67. Nature Editorial (2010). The party's over. Nature 468: 475.
68. Neve KA, Seamans JK, Trantham-Davidson H, (2004). Dopamine receptor signaling. J Recept Signal Transduct Res 24: 165-205. (Pubitemid 39332216)
69. Osswald H, Schnermann J, (2011). Methylxanthines and the kidney. Handb Exp Pharmacol 200: 391-412.
70. Phillips K, Luk A, Soor GS, Abraham JR, Leong S, Butany J, (2009). Cocaine cardiotoxicity: a review of the pathophysiology, pathology, and treatment options. Am J Cardiovasc Drugs 9: 177-196.
71. Poleszak E, Malec D, (2002). Adenosine receptor ligands and cocaine in conditioned place preference (CPP) test in rats. Pol J Pharmacol 54: 119-126. (Pubitemid 34546194)
72. Poleszak E, Malec D, (2003). Effects of adenosine receptor agonists and antagonists in amphetamine-induced conditioned place preference test in rats. Pol J Pharmacol 55: 319-326. (Pubitemid 36975198)
73. Reissig CJ, Strain EC, Griffiths RR, (2009). Caffeinated energy drinks-a growing problem. Drug Alcohol Depend 99: 1-10.
74. Richard D, Picard F, (2011). Brown fat biology and thermogenesis. Front Biosci 16: 1233-1260.
75. Riksen NP, Rongen GA, Smits P, (2009). Acute and long-term cardiovascular effects of coffee: implications for coronary heart disease. Pharmacol Ther 121: 185-191.
76. Roddy E, (2004). Bupropion and other non-nicotine pharmacotherapies. BMJ 328: 509-511.
77. Rosenberg H, Davis M, James D, Pollock N, Stowell K, (2007). Malignant hyperthermia. Orphanet J Rare Dis 24: 21.
78. Rusyniak DE, Banks ML, Mills EM, Sprague JE, (2004). Dantrolene use in 3,4-methylenedioxymethamphetamine (ecstasy)-mediated hyperthermia. Anesthesiology 101: 263.
79. Sasaki H, Hashimoto K, Inada T, Fukui S, Iyo M, (1995). Suppression of oro-facial movements by rolipram, a cAMP phosphodiesterase inhibitor, in rats chronically treated with haloperidol. Eur J Pharmacol 282: 71-76.
80. Schenk S, Partridge B, (1999). Cocaine-seeking produced by experimenter-administered drug injections: dose-effect relationships in rats. Psychopharmacology (Berl) 147: 285-290. (Pubitemid 30010549)
81. Schenk S, Horger B, Snow S, (1990). Caffeine preexposure sensitizes rats to the motor activating effects of cocaine. Behav Pharmacol 1: 447-451.
82. Schenk S, Valadez A, Horger B, Snow S, Wellman P, (1994). Interactions between caffeine and cocaine in tests of self-administration. Behav Pharmacol 5: 153-158. (Pubitemid 24153737)
83. Schindler CW, Zheng JW, Tella SR, Goldberg SR, (1992). Pharmacological mechanisms in the cardiovascular effects of methamphetamine in conscious squirrel monkeys. Pharmacol Biochem Behav 42: 791-796.
84. Schindler CW, Tella SR, Erzouki HK, Goldberg SR, (1995). Pharmacological mechanisms in cocaine's cardiovascular effects. Drug Alcohol Depend 37: 183-191.
85. Simola N, Tronci E, Pinna A, Morelli M, (2006). Subchronic-intermittent caffeine amplifies the motor effects of amphetamine in rats. Amino Acids 31: 359-363. (Pubitemid 44853456)
86. Sondermeijer HP, van Marle AG, Kamen P, Krum H, (2002). Acute effects of caffeine on heart rate variability. Am J Cardiol 90: 906-907.
87. 2A adenosine receptors diminishes the reinforcing efficacy of cocaine. Neuropsychopharmacology 31: 978-987.
88. Tariq M, Islam MW, al-Meshal IA, el-Feraly FS, Ageel AM, (1989). Comparative study of cathinone and amphetamine on brown adipose thermogenesis. Life Sci 44: 951-955. (Pubitemid 19084211)
89. Vanattou-Saïfoudine N, McNamara R, Harkin A, (2010a). Mechanisms mediating the ability of caffeine to influence MDMA ('ecstasy')-induced hyperthermia in rats. Br J Pharmacol 160: 860-877.
90. 1 receptor-mediated body temperature, heart rate and behavioural responses to MDMA ('ecstasy'). Psychopharmacology (Berl) 211: 15-25.
91. Vanattou-Saïfoudine N, Gossen A, Harkin A, (2011). A role for adenosine A(1) receptor blockade in the ability of caffeine to promote MDMA 'ecstasy'-induced striatal dopamine release. Eur J Pharmacol 650: 220-228.
92. 1 receptor mediated intracellular responses in the hypothalamus following co-administration of caffeine with MDMA. Basic Clin Pharmacol Toxicol 110: 283-289.
93. Weerts EM, Griffiths RR, (2003). The adenosine receptor antagonist CGS15943 reinstates cocaine-seeking behavior and maintains self-administration in baboons. Psychopharmacology (Berl) 168: 155-163. (Pubitemid 36851174)
94. West AR, Galloway MP, (1996). Regulation of serotonin-facilitated dopamine release in vivo: the role of protein kinase A activating transduction mechanisms. Synapse 23: 20-27. (Pubitemid 26138644)
95. Yamashita N, Hayashi A, Baba J, Sawa A, (1997). Rolipram, a phosphodiesterase-4-selective inhibitor, promotes the survival of cultured rat dopaminergic neurons. Jpn J Pharmacol 75: 155-159. (Pubitemid 27491550)
96. Yang A, Palmer AA, de Wit H, (2010). Genetics of caffeine consumption and responses to caffeine. Psychopharmacology (Berl) 211: 245-257.
97. Zeng C, Zhang M, Asico LD, Eisner GM, Jose PA, (2007). The dopaminergic system in hypertension. Clin Sci (Lond) 112: 583-597. (Pubitemid 46849549)